CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.

Please visit answersincme.com/860/IME_2025_00013162-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Toby Maher, MB, MSc, PhD, FRCP; and Justin Oldham, MD, MS. In this activity, experts explore advances in ILD care, including personalized, multidisciplinary approaches to integrate novel antifibrotic therapy and enhance patient engagement. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel antifibrotic therapy in interstitial lung disease (ILD); Apply the latest clinical data on novel antifibrotic therapy to therapeutic decision-making in ILD; and Outline multidisciplinary strategies to enhance the care of patients with ILD who are receiving antifibrotic therapies.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC.